Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06027554 · ClinicalTrials.gov registry record · Phase 2
The Mito-Frail Trial: Effects of MitoQ on Vasodilation, Mobility and Cognitive Performance in Frail Older Adults
A Phase 2 study of Aging and Mild Cognitive Impairment, sponsored by UConn Health.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT06027554: Recruiting Phase 2 study of Aging and Mild Cognitive Impairment, sponsored by UConn Health.
NCT06027554 is a Phase 2 study of Aging and Mild Cognitive Impairment that is actively recruiting participants, run by UConn Health. The registered enrollment target is 60 participants, below the 2,194-participant average among 262 other Aging trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06027554, a Phase 2 study of Aging and Mild Cognitive Impairment, is actively recruiting participants, sponsored by UConn Health.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to test the effects of MitoQ supplementation in older adults and frail older adults with physical dysfunction and/or cognitive dysfunction. The main question\[s\] it aims to answer are: * To compare vascular function, oxidative stress levels, and physical and cognitive function among older adults and frail older adults with physical and cognitive dysfunction * To determine whether MitoQ supplementation has the potential to improve vascular function in central and cerebral vessels * To determine whether MitoQ supplementation can enhance physical and cognitive capabilities.
Primary Outcome
Assess Femoral artery through Passive Leg Movement and Brachial artery flow-mediated dilation (% \[relative\] and mm \[absolute\])
Conditions Studied
Interventions
- DRUG Mitoquinone Mesylate
- DIETARY_SUPPLEMENT Placebo capsule
Study Locations (1)
Connecticut
- UConn Health - Farmington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2024-10-07 |
| Est. Completion | 2028-02-01 |
| Phase | Phase 2 |
What NCT06027554 shows while recruiting
NCT06027554 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 2,194-participant average among 262 other Aging trials with a reported enrollment target (97% lower).
The record links to 3 conditions, with Aging appearing as the primary indexed condition, and to 2 interventions - of which Mitoquinone Mesylate is the first listed.
NCT06027554 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT06027554 about?
NCT06027554 is a clinical study titled "The Mito-Frail Trial: Effects of MitoQ on Vasodilation, Mobility and Cognitive Performance in Frail Older Adults". The goal of this clinical trial is to test the effects of MitoQ supplementation in older adults and frail older adults with physical dysfunction and/or cognitive dysfunction. The main question\[s\] it aims to answer are: * To compare vascular function, oxidative stress levels, and physical and cogn...
What is the current status of trial NCT06027554?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2024-10-07. Estimated completion is 2028-02-01.
What conditions does trial NCT06027554 study?
This clinical trial studies the following conditions: Aging, Mild Cognitive Impairment, Frailty.
What interventions are being tested in trial NCT06027554?
The interventions under investigation include: Mitoquinone Mesylate (DRUG), Placebo capsule (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT06027554?
This trial is sponsored by UConn Health, which has 178 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06027554 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Aging
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06027554's enrollment target sits among peer trials
60 137th of 262 higher than 120 of 262 other Aging trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Aging trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Empagliflozin Reversal of Arterial StiffnEss in Aging
RECRUITING · Phase 2
-
Nicotinamide Riboside for Treating Elevated Systolic Blood Pressure and Arterial Stiffness in Middle-aged and Older Adults
RECRUITING · Phase 2
-
Exercise to Improve Brain Health in Older African Americans
RECRUITING · Phase 2
-
Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV
RECRUITING · Phase 2
-
Acetate and Age-associated Arterial Dysfunction
RECRUITING · Phase 2
-
Effectiveness of Alternative Therapies in Maintaining Weight Loss Achieved by GLP-1 Medications Post-Cessation
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI